Dr Reddy's launches anti-epilepsy drug in US, taps into $37 mn market

Dr Reddy's Laboratories Ltd on Tuesday announced that it has launched antiepileptic drug, Levetiracetram in Sodium Chloride injection, in multiple strengths, in the US market.

The drug maker launched Levetiracetram in Sodium Chloride Injection in 500 mg/100 mL (5 mg/mL), 1,000 mg/100 mL (10 mg/mL), and 1,500 mg/100 mL (15 mg/mL) single-dose infusion bags, a therapeutic equivalent generic version of HQ Specialty Pharma Corporation's Levetiracetam in Sodium Chloride Injection.

The drug has been approved by the US Food and Drug Administration (USFDA), a press release from Dr Reddy's said.

The Levetiracetam in Sodium Chloride Injection brand and generic had US sales of approximately $37 million moving annual turnover for the most recent twelve months ending in April 2018, according to IMS Health, the release said.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)